Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsDan Oren, MD, BS
Associate Professor of Psychiatry (Adjunct)DownloadHi-Res Photo
About
Copy Link
Titles
Associate Professor of Psychiatry (Adjunct)
Education & Training
- MD
- Yale University (1984)
- BS
- Yale University, Chemistry (1979)
Research
Copy Link
Overview
Medical Research Interests
Chronobiology Phenomena; Depressive Disorder, Major; Mood Disorders
Research at a Glance
Yale Co-Authors
Frequent collaborators of Dan Oren's published research.
Publications Timeline
A big-picture view of Dan Oren's research output by year.
Research Interests
Research topics Dan Oren is interested in exploring.
Angela Cappiello, MD, PhD
Paul Desan, MD, PhD
John Krystal, MD
Ralitza Gueorguieva, PhD
Vladimir Coric, MD
Gerard Sanacora, PhD, MD
81Publications
7,261Citations
Depressive Disorder, Major
Mood Disorders
Publications
2020
Carbon monoxide: a critical physiological regulator sensitive to light
Oren DA, Sit DK, Goudarzi SH, Wisner KL. Carbon monoxide: a critical physiological regulator sensitive to light. Translational Psychiatry 2020, 10: 87. PMID: 32152296, PMCID: PMC7062897, DOI: 10.1038/s41398-020-0766-1.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHealthy female volunteersAntidepressant effectsPeripheral bloodBlood samplesFemale volunteersConfirmatory studiesPhysiological regulatorPeripheral blood samplesContinuous exposureBright light exposureCritical physiological regulatorHuman evidenceVivo modelNonseasonal depressionBlood carbon monoxideMean carbon monoxideBright white lightAdditional volunteersVolunteersPutative roleCircadian rhythmExposureBloodTherapeutic lightBright light
2015
Changes in melatonin synthesis parameters after carbon monoxide concentration increase in the cavernous sinus.
Romerowicz-Misielak M, Oren D, Sowa-Kucma M, Tabecka-Lonczynska A, Gilun P, Stefanczyk-Krzymowska S, Koziorowski M. Changes in melatonin synthesis parameters after carbon monoxide concentration increase in the cavernous sinus. Journal Of Physiology And Pharmacology 2015, 66: 505-14. PMID: 26348075.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsOphthalmic venous bloodVenous bloodNocturnal melatonin riseMelatonin levelsMelatonin riseWinter seasonal affective disorderNocturnal melatonin peakSeasonal affective disorderHour infusionCavernous sinusVenous sinusesNon-physiological changesAutologous blood plasmaAffective disordersSynthesis of melatoninBright light effectsBloodAANAT protein levelsMelatonin peakProtein levelsAcute impactSinusTreatmentBlood plasmaParallel changes
2013
SAD and the Not-So-Single Photoreceptors
Oren DA, Koziorowski M, Desan PH. SAD and the Not-So-Single Photoreceptors. American Journal Of Psychiatry 2013, 170: 1403-1412. PMID: 23929223, DOI: 10.1176/appi.ajp.2013.13010111.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMolecular mechanismsSeasonal affective disorderCircannual regulationCritical regulatorTetrapyrrole pigmentsDevelopment of therapiesRole of rodsInfluence of lightPhotoreceptorsCone photoreceptorsLight treatmentAntidepressant effectsPhysiologyAnimal modelsAffective disordersRecent studiesSingle photoreceptorsPhototransductionRegulatorDisordersRegulationMechanismGasotransmitterRolePigments
2010
Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorder
Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang S, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG. Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorder. Depression And Anxiety 2010, 27: 417-425. PMID: 20455246, DOI: 10.1002/da.20695.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdolescentAdultAgedAnti-Anxiety AgentsAnxiety DisordersCitalopramDiagnostic and Statistical Manual of Mental DisordersDouble-Blind MethodFemaleHumansMaleMiddle AgedPharmacogeneticsPhenotypePolymorphism, Single NucleotidePsychometricsPyrazolesReceptors, Corticotropin-Releasing HormoneSeverity of Illness IndexTriazinesYoung AdultConceptsGeneralized anxiety disorderSingle nucleotide polymorphismsHamilton Anxiety Scale (HAMA) total scoreAnxiety disordersFactor receptor 1 antagonistActive comparator armCorticotropin-releasing factor receptorsActive comparator trialsPlacebo-controlled trialCorticotropin-releasing factor receptor 1 antagonistTreatment of GADPrimary outcome measurePlexin-A2Receptor 1 antagonistScale total scoreCRF-1 receptor antagonistClass of agentsComparator trialsComparator armPrimary outcomeActive comparatorEntire cohortRandomized subjectsReceptor antagonistMean change
2009
Light and non-visual photoreception
Oren D, Desan P. Light and non-visual photoreception. 2009, 131-142. DOI: 10.1093/med/9780199544288.003.0008.Peer-Reviewed Original ResearchAripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study
Young A, Oren D, Lowy A, McQuade R, Marcus R, Carson W, Spiller N, Torbeyns A, Sanchez R. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. The British Journal Of Psychiatry 2009, 194: 40-48. PMID: 19118324, DOI: 10.1192/bjp.bp.108.049965.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsWeek 12Young Mania Rating Scale (YMRS) total scoreDouble-blind aripiprazoleHaloperidol-treated patientsTolerability of aripiprazoleExtrapyramidal adverse eventsScale total scoreMasked treatmentAdverse eventsClinical improvementAcute maniaAripiprazole monotherapyBipolar maniaMixed episodesEffective therapyEffect therapyAripiprazoleAdditional weeksHaloperidolWeek 3PlaceboPatientsTotal scoreTherapyMania
2008
A Randomized, Double-Blind, Placebo-Controlled Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients With Alzheimer's, Vascular, or Mixed Dementia
Rappaport S, Marcus R, Manos G, McQuade R, Oren D. A Randomized, Double-Blind, Placebo-Controlled Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients With Alzheimer's, Vascular, or Mixed Dementia. Journal Of The American Medical Directors Association 2008, 10: 21-27. PMID: 19111849, DOI: 10.1016/j.jamda.2008.06.006.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsAgitation-Calmness Evaluation ScaleIM aripiprazoleIM placeboMixed dementiaIntramuscular aripiprazoleDoses 2 hoursIncidence of oversedationTreatment of agitationHealthcare facilitiesPreliminary efficacy analysisAdverse event reportingNegative Syndrome ScaleLong-term careAcute agitationEfficacy analysisTolerability studyPlaceboPEC scoresAripiprazoleGreater incidenceSyndrome ScaleGreater efficacyPatientsVital signsDementia
2007
Intramuscular Aripiprazole for the Treatment of Acute Agitation Associated with Schizophrenia: Sub-analysis of a Double-blind, Controlled, Dose-ranging Study
Kungel M, Czaniera R, Ebrecht M, Werner C, Oren D, McQuade R, Modell S. Intramuscular Aripiprazole for the Treatment of Acute Agitation Associated with Schizophrenia: Sub-analysis of a Double-blind, Controlled, Dose-ranging Study. Pharmacopsychiatry 2007, 40 DOI: 10.1055/s-2007-991772.Peer-Reviewed Original ResearchCitationsEfficacy and Safety of Oral Aripiprazole Compared with Haloperidol in Patients Transitioning from Acute Treatment with Intramuscular Formulations
DANIEL D, CURRIER G, ZIMBROFF D, ALLEN M, OREN D, MANOS G, MCQUADE R, PIKALOV A, CRANDALL D. Efficacy and Safety of Oral Aripiprazole Compared with Haloperidol in Patients Transitioning from Acute Treatment with Intramuscular Formulations. Journal Of Psychiatric Practice 2007, 13: 170-177. PMID: 17522560, DOI: 10.1097/01.pra.0000271658.86845.81.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAcute DiseaseAdministration, OralAdolescentAdultAgedAntipsychotic AgentsAripiprazoleDouble-Blind MethodDyskinesia, Drug-InducedFemaleHaloperidolHumansInjections, IntramuscularMaleMiddle AgedPiperazinesPsychiatric Status Rating ScalesPsychomotor AgitationPsychotic DisordersQuinolonesSchizophreniaConceptsOral aripiprazoleOral formulationHaloperidol IMOral phaseIntramuscular formulationEfficacy measuresSchizoaffective disorderExtrapyramidal symptom-related adverse eventsPrimary efficacy measureStudy days 1Negative Syndrome ScalePlacebo IMAcute treatmentAdverse eventsGood tolerabilityClinical statusMean changePEC scoresPatientsDay 1HaloperidolAripiprazoleSyndrome ScaleInitial benefitComponent scoresIntramuscular Aripiprazole in the Control of Agitation
CURRIER G, CITROME L, ZIMBROFF D, OREN D, MANOS G, MCQUADE R, PIKALOV A, CRANDALL D. Intramuscular Aripiprazole in the Control of Agitation. Journal Of Psychiatric Practice 2007, 13: 159-169. PMID: 17522559, DOI: 10.1097/01.pra.0000271657.09717.e2.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAntipsychotic AgentsAripiprazoleArousalBipolar DisorderDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleHaloperidolHumansHypnotics and SedativesInjections, IntramuscularLorazepamMaleMiddle AgedMulticenter Studies as TopicPiperazinesPsychiatric Status Rating ScalesPsychomotor AgitationQuinolonesRandomized Controlled Trials as TopicSchizophreniaSchizophrenic PsychologyTreatment OutcomeConceptsBipolar I disorderPEC scoresAripiprazole injectionI disordersBaseline agitationSecond injectionNegative Syndrome Scale Excited ComponentBaseline levelsSecondary analysisControl of agitationImportant clinical issueIntramuscular aripiprazoleAnalysis 3Clinical trialsAgitation symptomsMean changeNonspecific sedationPatientsBaseline scoresClinical issuesPlaceboAnalysis 2Analysis 1Study periodSchizophrenia
Get In Touch
Copy Link
Contacts
Email